Brief: MedinCell Announces Inclusion Of First Participants In New Covid-19 Prophylaxis Clinical Trial SAIVE

Medincell SA

28/03/2022 16:55

March 28 (Reuters) - Medincell SA  MEDCL.PA :
    * MEDINCELL: INCLUSION OF FIRST PARTICIPANTS IN NEW COVID-19
PROPHYLAXIS CLINICAL TRIAL SAIVE
    * INTERIM DATA ARE EXPECTED MID 2022
    * FIRST PARTICIPANTS OF SAIVE STUDY HAVE BEEN ADMINISTERED
LAST
FRIDAY
    * SAIVE IS A 400-PARTICIPANT, MULTICENTER, RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH AN INDEPENDENT DATA
MONITORING COMMITTEE, CONDUCTED IN EUROPEAN UNION
    * A MORE THAN 3-MONTH ACTIVE FORMULATION IS READY TO ENTER
REGULATORY DEVELOPMENT.
    * SAIVE AIMS AT VALIDATING EFFICACY IN PROPHYLAXIS AGAINST
COVID-19 OF ADMINISTRATION OF IVERMECTIN IN ORAL DAILY FORM
    * SAIVE FOLLOWS A PHASE 1 CLINICAL STUDY CONDUCTED BY
MEDINCELL
THAT SUCCESSFULLY CONFIRMED SAFETY OF DAILY, ORAL IVERMECTIN
ADMINISTRATION OVER A LONG PERIOD OF TIME

Source text for Eikon:  ID:nBw3ljkbfa 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))